Neumora Therapeutics' (NMRA) readout of its first phase 3 trial of navacaprant in major depressive disorder was a "significant miss," but the company still has two more chances to go, Mizuho Securities said in a note Friday.
Two phase 3 trials are still ongoing, with topline data readouts from both studies slated for H1, Mizuho analyst Graig Suvannavejh said, adding the company can make adjustments to these two studies given the negative results from the first trial although timelines might be affected.
The company is expected to provide a navacaprant program update in the next few weeks and Mizuho said it will wait for that update before revisiting its estimates and views on the company.
"With [Neumora] now trading at negative enterprise value, but having a cash runway to mid-2026 and other pipeline programs, the shares look oversold," according to the note.
Mizuho has an outperform rating on Neumora and $20 price target.
Neumora shares were rising more than 18% in recent trading.
Price: 2.33, Change: +0.36, Percent Change: +18.27
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.